
Relapsed or refractory mediastinal B-cell lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-20082617

[Expand/Collapse all sections]Expand all

-   Background
-   Process
-   Resources

This document outlines details of the Pharmaceutical Benefits Scheme PBS
subsidised pembrolizumab for patients with relapsed or refractory
Mediastinal B-cell lymphoma. A patient’s treatment must not exceed a
total of 35 cycles in a lifetime.

Mediastinal B-cell lymphoma and listing dates

Mediastinal B-cell lymphoma is a cancer of the immune system.

Listing dates are as follows:

-   pembrolizumab - 1 September 2020

See Written Authority Required Drugs for further information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
being treated.

The Resources page contains links to restriction and item codes, contact
details, application forms, and the Pharmaceutical Benefits Scheme
(PBS)and Services Australia websites.

Related links

Written Authority Required Drugs

Processing Written Authority Required Listings

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA)

                                   

-   Services Australia ABN 90 794 605 008 
